Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry. This solution includes (1) a panel of highly diverse synthetic naïve antibody phage display libraries, (2) several target class specific antibody phage display libraries against difficult-to-drug targets, (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization and (4) a high-throughput antibody expression service. To highlight the power of this platform, our anti-SARS-CoV-2 antibody discovery and optimization efforts will be presented.

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.
  • Synthetic DNA Technologies Enable Fast 
  • Responsive SARS-CoV-2 Antibody Discovery and Optimization
  • 1592246115-4c039d5f7a7af9e5
    Aaron K. Sato, Ph.D.
    Chief Scientific Officer, Biopharma, Twist Bioscience
    Aaron is CSO of the Biopharma Vertical at Twist Bioscience. Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.